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ABSTRACT 
 
Introduction: The genetics of the most common neurological 
disorders, including epilepsy, with mendelian inheritance has been 
dissected in the last twenty years. However the genetic etiology of 
some rare epileptic conditions is still unknown. This research project 
focuses on rare autosomal recessive (AR) epileptic conditions. The 
genetic data obtained so far indicate that about half of cases affected by 
autosomal recessive disorders carry a homozygous mutation descending 
from a unique ancestor (founder effect). The putative mutation is 
contained within a segment of the DNA, called “identical by descent” 
(IBD), that is transmitted along the generations. This segment is 
characterized by a set of contiguous homozygous polymorphisms 
(SNP) and may be detected using a genome wide genotyping approach, 
namely the “homozygosity mapping” which allows the typing of a great 
number of SNP   in order to detect very small IBD segments. Thus 
nuclear families (sib-pairs) originating from restricted areas can be 
genotyped in order to identify a new AR disease genes. In addition the 
novel sequencing methods can further follow up these regions allowing 
the rapid screening of hundreds genes. 
Material and methods: Families with at least two affected siblings 
affected by a rare epileptic condition sharing the same clinical pictures 
have been selected. Parental ancestors should have originated from the 
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same geographical area. The affected relatives, their parents and 
unaffected siblings have been genotyped using the Axiom Genome 
wide human assay (Affymetrix). A classical linkage analysis has been 
performed in case of a negative result from the homozygosity mapping 
approach for families with more than two affected relatives. 
Homozygosity regions have been then analyzed using a classical 
Sanger sequencing  or using a next generation sequencing approach. 
Results and discussion: homozygosity mapping allowed the 
identification of homozygosity stretches in one out of four families. 
Combined analysis (homozygosity mapping plus linkage) allowed the 
identification of narrow homozygosity areas in two families. The 
analysis of the genes included in the isolated stretches is ongoing. The 
negative result in family 3 and the eventuality of a negative result for 
the ongoing sequencing analysis can be explained hypothesizing a 
different inheritance pattern (X-linked, low penetrance heterozygosity, 
non mendelian and digenic inheritance, compound heterozygousity) or 
methodology limiting issue (mutation contained in a segment shorter 
than the homozygosity mapping cut off).  
 
Key words: Epilepsy; homozygosity mapping; genetic 
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INTRODUCTION  
 
Genetic and epilepsy 
The genetics of most common single-gene neurological disorders has 
been dissected in the last twenty years. However, the etiology of 
several rare Mendelian neurological conditions is still unknown with 
significant implications for diagnosis, genetic counseling and therapy. 
Human epilepsy is a common and heterogeneous condition in which 
genetic plays an important etiological role [1] [2, 3]. 
The approach to epilepsy genetics has, until relatively recently, been 
based on Mendelian genetics, relying on the ascertainment of large 
pedigrees, linkage analysis of polymorphic markers to established 
disease-associated loci, and positional cloning within these loci to 
identify the pathogenic gene mutation [4]. Inheritance is autosomal 
dominant in many of the familial epilepsy syndromes [1, 5] in which 
mutations have been identified, with all genes with the exception of 
LGI1[6], encoding for subunits of ion channels (KCNQ2, KCNQ3, 
SCN1A, SCN1B, SCN2A) [7-10] or neurotransmitter receptors 
(CHRNA4, CHRNA2, GABRG2) [11, 12]. Autosomal recessive 
inheritance has also been found in many epileptic syndromes. These 
vary from very severe syndromes such as progressive myoclonic 
epilepsies (Lafora disease, Unverricht Lundborg disease, sialidoses, 
ceroid lipofuscinoses etc) [13-15] to milder phenotype syndromes such 
as autosomal recessive benign myoclonic epilepsy of infancy [16, 17]. 
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The identification of autosomal recessive disease genes- 
Homozygosity mapping 
 
So far the identification of genes for autosomal recessive conditions 
has been constrained by methodological issues such as the shortage of 
informative families for linkage analysis, the lack of very dense maps 
of polymorphic markers and the availability of efficient and low-cost 
platforms for genotyping and sequencing. 
The extensive genetic data collected so far on rare Mendelian diseases 
indicate that up to half of cases affected by autosomal recessive (AR) 
disorders carry a homozygous mutation descending from a unique 
ancestor, a phenomenon called “founder effect”. The causative 
mutation is contained within a chromosomal segment which is 
transmitted along the generations (i.e. identical-by-descent, IBD) and 
may vary in size according to the number of recombination events 
occurring during transmission [18, 19]. Thus, as the ancestor is far in 
the past and number of transmission increases, the size of the IBD 
segment harboring the mutation decreases. The IBD segment is 
characterized by a set of contiguous homozygous single nucleotide 
polymorphisms (SNP) and may be detected by genome-wide 
genotyping. This approach named “homozygosity mapping” has been 
applied to large consanguineous families presenting with neurological 
disorders, where the common ancestor is close and the size of the IBD 
segment is large enough to be detected by low-density genotyping [19] 
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[20] [21] [22] [23] [24]. The proximity of the ancestor allowed several 
IBD segments to be transmitted and thus multiple affected individuals 
are required to identify that one co-segregating with the disease [19]. 
The current microarray-based platforms allow the typing of hundreds-
thousands to million single nucleotide polymorphisms (SNPs) to detect 
very small IBD segments originating from very far ancestors [25]. 
Thus, the study of non-consanguineous nuclear families such as 
affected sib-pairs originating from geographic isolates may allow the 
accurate localization of new AR disease genes, indeed the chance to 
inherit several IBD segments from a far ancestor by chance is low. 
In addition the novel sequencing methods  (next generation 
sequencing) [26] [27, 28] allow the rapid screening of hundreds of 
genes and the identification of large or multiple IBD segments is not a 
limiting factor toward the identification of the causative mutation. 
 
 
 
The main goal of this project is to identify novel genes for rare AR 
epileptic syndromes by using homozygosity mapping. This study is part 
of a major European project and has been conducted in collaboration 
with the “neurodegenerative and muscle disease” laboratory of the 
Gaslini Institute in Genova, and has been supported by the Current 
Research Activity of the Gaslini Institute. 
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MATERIAL AND METHODS 
 
Families 
The selection of families is a critical issue to exploit successfully 
homozygosity mapping. We focused our strategy mostly on pairs of 
affected siblings rather than large consanguineous families with 
multiple affected individuals as such nuclear families are quite common 
in the clinical practice. This approach hypothesizes that there is a 
unique homozygous mutation descending from a common ancestor and 
that this common ancestor should precede the proband(s) by several 
generations allowing a unique or a few IBD segments of small size to 
be transmitted. Thus, in order to select a suitable samples for 
homozygosity mapping we evaluated families with at least two 
relatives (sib-pairs) affected by a rare classified or unclassified epileptic 
syndrome of unknown genetic etiology, showing an autosomal 
recessive pattern of inheritance. Families lacking close consanguinity 
(consanguinity was accepted further than second generation ancestors) 
and originating from a restricted geographical region or community 
(ideally less than 100.000 inhabitants) were the most suitable 
candidates for this approach, as the disease causative mutation is likely 
descending from a unique ancestor.  
The sib-pairs underwent a full diagnostic work-up to exclude common 
genetic conditions (Karyotype, array-CGH analysis, Fragile X 
syndrome). Also they have been screened for the most common genetic 
conditions that would be differentially diagnosed according to the 
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clinical picture: for example in case of a progressive myoclonic 
epilepsy siblings have been screened for Unverricht Lundborg disease, 
Lafora disease [13], sialidoses,  ceroid lipofuscinoses [29], 
mithocondrial encephalomyopathy with ragged red fibers (MERFF) 
[14]. 
Peripheral blood was collected from the probands and their available 
first degree relatives to obtain high-molecular weight genomic DNA. In 
addition we obtained DNA samples from at least 50 ethnically-matched 
controls. 
 
 
 
Genotyping and homozygosiy mapping 
Patients and their first degree relatives have been genotyped by using a 
high-density SNP array (Axiom Affymetrix GW array plate 675 K). 
This assay contains 675.000 SNP markers that cover the entire genome.  
The SNP genotype files have been then uploaded on the 
homozygositymapper application [30] to identify runs of homozygous 
(ROH) SNPs. Intervals had to meet the limit of at least 100 SNPs or 1 
MB in size to be further followed up. This cut-off has been chosen on 
the basis of recent population studies showing that ROHs shorter than 
around 1.5 Mb may reflect patterns of ancient origin rather than effects 
of recent endogamy and may account up to 2-3% of the autosomal 
genome and that individuals with a common maternal and paternal 
ancestor in the preceding six generations showed ROHs sized more 
than 5 Mb[31]. However ROHs larger than 1.5 Mb accounting for 0.2-
0.3% of the autosomal genome are also found in the general 
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population[31]. Thus ROHs were not further followed up in case they 
were present also in the parents or they were known to be a highly 
conserved region among the populations (i.e. centromeric region) [31], 
or present in ethnically matched controls.  
In the availability of families with more than two affected siblings or 
other affected relatives and in case of negative result by homozygosity 
mapping, we also considered the possibility to run a classical linkage 
analysis (Merlin) [32]. Since homozygous areas have to be in linkage, 
while it is not always true the contrary, we also considered to match 
linkage data with homozygosity mapping data in order to detect ROH 
(smaller than 1.0 Mb o 100 SNP) segments within linkage areas.  
 
 
Brief description of the homozygosity mapping technique 
Once purified genomic DNA has been obtained, this is digested using 
restriction enzymes and legated to an adaptor support. An allele 
specific extension is performed by using three different oligos: two are 
specifically designed to recognize the two alleles while the third is able 
to recognize the correct position on the array. Fragments are then 
amplified through a PCR reaction with universal primers and labeled 
with two different fluorochromes (red and green). Array hybridization 
and washing is then performed on the dedicated high-density SNP array 
(Axiom Affymetrix GW array plate 675 K). The fluorescent intensity 
generated from the beads is detected by a scanner (using the GeneTitan 
reader scanner)(figure 1a). A red color indicates homozygosity for one 
allele,  a green color indicates homozygosity for the second allele while 
a yellow color indicates heterozygosity. 
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Genotype files are then uploaded into the homozygositymapper online 
application that plots the genome wide homozygosity as bar charts with 
red bars indicating the most promising genomic regions (figure 1b). 
Furthermore the GeneDisteller engine provides a candidate gene search 
in that area [33] 
 
 
Sequencing of candidate genes 
If the identified homozygous region(s) harbored less than 20 genes we 
performed conventional Sanger sequencing to detect point mutations. 
Alternatively we used the next generation exome sequencing (by using 
the SureSelectXT target enrichment system) approach to screen large 
set of candidate genes [27, 28]. This approach select non-synonymous, 
splice site or indel sequence variants in each of the individuals. Then 
the result is compared to the exome sequences of healthy controls and 
database SNP (dbSNP)  to exclude common variations. 
If the ROHs harbored many genes (hundreds), hypothesis of candidate 
genes has also been conducted through literature search and database  
data comparison (ensemble genome Hg 18 
http://may2009.archive.ensembl.org/index.html).  
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RESULTS 
 
Four families recruited at the Epilepsy Centre of the University of 
Naples Federico II have been included in this study: 
 
Family 1 
This family originates from Naples (see figure 2). It has four out of five 
siblings affected from Familial Infantile Myoclonic Epilepsy (FIME). 
This is a recessive idiopathic epileptic syndrome that starts in early 
infancy showing myoclonic seizures, febrile convulsions, and tonic-
clonic seizures (see table 1) [34]. All the affected siblings showed the 
same clinical picture consistent with this syndrome including negative 
brain resonance magnetic imaging.  
A locus on 16p13 has been mapped for this syndrome[35] but our 
family did not show any linkage with it. Also this family resulted to be 
negative for  TBC1D24 an ARF 6 interacting protein of unknown 
function that has been found to be mutated in the same family reported 
by Zara in 2000[17]  
High density homozygosity mapping did not show any homozygous 
area. 
A classical linkage analysis has been then performed since this family 
offered more than two affected members. A small linkage area on the 
long arm region of chromosome 1 has been identified. Looking into 
this area we could isolate a small homozygous area spanning from 
marker 284 to marker 303 (see figure 3a). A study of the included 
genes in this area pointed out a single gene, the Regulator of G-protein 
Signaling 21 (RGS 21, see figure 3b),  whose function is only partially 
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known (involvement in taste signaling)[36]. Even though it does not 
look a good candidate gene for our family we are now proceeding with 
a Sanger sequencing of the gene.  
 
 
Family 2 
This family originates from Naples (see image 4). The probands (IV:1 
and IV:3) are two sisters affected from a Progressive form of 
Myoclonic Epilepsy with ataxia and mental retardation (see fig.2) [37]. 
Brain MRI showed a slight cerebellar atrophy for both of them. The 
clinical picture resembled Unverricht-Lundborg disease (ULD) (see 
table 2). Laboratory findings and molecular analysis excluded this 
diagnosis and other possible causes of Progressive Myoclonic 
Epilepsy/Progressive Myoclonic ataxia (Unverricht Lundborg disease, 
Lafora disease, myoclonic epilepsy with red ragged fibers, neuronal 
ceroid lipofuscinoses and sialidoses) [13]. The two cousins (IV:5 e 
IV:6) presented with a very similar clinical picture.  
High density homozygosity mapping analysis did not show any 
homozygous stretch. However since the blood samples of their first 
degree affected cousins were available, we performed a classic linkage 
analysis.  One little stretch on chromosomes 2 and four little stretches 
on chromosome 17 were found (see image 5 and 6). Another little area 
on chromosome 3 has been discarded since it was also present in their 
parents. A homozygous mapping has been then performed in these 
areas. The result from the combined analysis allowed the detection of a 
small area on chromosome 2 (from marker rs35182736 to marker 
rs36055280) (see figure 5a) and four small areas on chromosome 17 
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(from marker rs12051702 to marker rs8074678; from marker 
rs10971025 to marker rs9754; from marker  rs2269858 to marker 
rs7219346; from marker rs11079043 to marker rs11871636) (see figure 
6 a, c, e, g). A list of the included genes is provided in the figure 5b, 6b, 
6d, 6f, 6h and in the supplementary data file 1. 
These areas harbor totally less than 30 genes. An exome sequencing is 
undergoing. 
 
 
 
Family 3  
This family originates from Naples (see image 7): the probands are two 
siblings affected from drug-resistant epilepsy (Lennox Gastaut like), 
mental retardation, visual failure with retinitis pigmentosa and learning 
disabilities (see table 3). They also presented with short stature, 
macroglossia, obesity, precocious puberty, heart hypertrophy, 
hypothyroidism, partial teeth agenesis, skeletal abnormalities (see 
image 8). Brain MRI data are not available but they have been reported 
as normal. The clinical pictures drove the attention to Bardet Biedl 
syndrome (BBS) even though they were not showing polydactyly nor 
renal failure (see table 3) [38]. They have been screened for common 
BBS allele (BBS1 M309R and BBS10 C91fsX95) and they were found 
to be negative. 
High density homozygosity mapping has been performed and the result 
showed no homozygous areas. In this family linkage analysis was not 
performed since no other affected members were available.  
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Family 4 
This family originates from a small village in Naples (Bacoli; 26500 
inhabitants) (see image 9): the probands are two siblings affected from 
drug-resistant epilepsy (Lennox Gastaut like), severe mental 
retardation, peripheral neuropathy, psychosis, visual failure and 
deafness (see table 4). They also presented with short stature, 
macroglossia, skeletal abnormalities and facial dysmorphisms (see 
image 10). Brain MRI showed the same abnormalities in both the 
brothers, namely white matter altered signal in the ventricle posterior 
area; dysmorphic features of the brainstem and thinning of the corpus 
callosum.  The pedigree of this family showed a consanguineous 
marriage in the fourth previous generation. This has not been 
considered as an exclusion criteria since it was further than the third 
ancestor generation. The high density homozygosity mapping has 
shown two homozygous stretches, on chromosome 2 (from genomic 
position 176414781bp to genomic position 243261751bp) and 19 (from 
genomic position 20799670bp to genomic position 39641146 bp) (see 
image 11). The area on chromosome 2 harbors 626 genes, while the 
area on Chromosome 19 harbors 352 genes. The study of the candidate 
genes through the gene distiller software is undergoing and candidate 
genes will be sequenced as appropriate.  
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DISCUSSION AND CONCLUSIONS  
 
Data reported from this study are heterogeneous reflecting the 
heterogeneous clinical pictures of the selected families. Overall high 
density homozygosity mapping allowed the detection of two 
homozygous stretches in one out of four families (family 4).  In family 
2 we were able to isolate 5 narrow homozygous areas by combining 
high density homozygosity mapping and classic linkage analysis. In 
family 1 a  homozygous area has been isolated using classical linkage 
analysis and  studying the haplotype. The genes included in these 
stretches are under screening through a next generation sequencing 
approach for family 2 and a classic Sanger sequencing for family 1.  
We will hopefully find a mutation within the narrowed regions. 
However a possible negative result need to be taken into account. This 
possibility can be explained hypothesizing a different pattern of 
inheritance that cannot be detected by homozygosity mapping (X-
linked, low penetrance heterozygosity, non mendelian and digenic 
inheritance, compound heterozygosity etc).  Other possible 
explanations may include  methodology issues (mutations within areas 
less than 1.0 MB or less than 100 SNP).  
We failed to show any area for family 3 which can be explained by one 
of the previous reasons. Compound heterozygosity seems to be the best 
explanation. Indeed up to half recessive traits are reported to be 
coumpound heterozygous [19]. Theoretically a lower SNPs cut-off 
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could be considered to find out a gene contained in a narrower 
homozygous area. However ROHs smaller than 1 Mb are too common 
in the general population and the eventuality to find many ROHs is 
likely to occur[31]. Also the interpretation of the data would not be 
easy to address.  
In our opinion homozygosity mapping is a valuable tool to analyze 
nuclear families with siblings affected from the same neurological 
condition suggesting a recessive inherited trait. Furthermore a 
combination of different genetic techniques can enhance the likelihood 
of finding new mutations. Probably a more detailed selection of the 
criteria would be useful to get more consistent results. 
 
According to the European Organization for Rare Diseases (Eurodis), 
rare disease (i.e. pathological conditions with population 
prevalence<1/2000) account for more than 5000 different forms and 
affects cumulatively about 6-8% of the general population. The 
etiology of about 80% of these disorders is presumed to be genetic even 
though in many instances the defects have been not yet characterized. 
Among these the autosomal recessive epileptic disorders are 
individually rare, but cumulative are not infrequent and are routinely 
seen at the Epilepsy Centre of the Federico II University. The 
phenotypes we selected for this study represent a heterogeneous group 
characterized by different epileptic conditions, mental retardation, 
dysmorphisms, slight brain MRI abnormalities and other organs 
involvement. These conditions show a complex management and raise 
puzzling clinical issues. The dissection of the genetic etiology is a 
critical step toward the diagnosis, genetic counseling and in future, 
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treatment. This ongoing project will hopefully allow the identification 
of novel disease genes responsible for these unknown clinical 
conditions and help with their clinical management.  
 
 
FUTURE STUDIES 
Future studies will be needed to help clarifying the function of these 
putative genes and consequently the phenotypic spectrum of the 
conditions. In the future we aim to follow up the putative mutations to 
assess their pathogenic effect. This will be done using by bioinformatic 
tools (endeavor ranking 
http://homes.esat.kuleuven.be/~bioiuser/endeavour/index.php) to 
explore whether they affect an evolutionary conserved aminoacid  or a 
functional domain of the protein or alter its correct folding. Cellular 
studies will be performed to experimentally evaluate the impact of 
mutations on cell survival and differentiation and on specific cellular 
functions by overexpressing wild-type and mutant proteins in neuronal 
or glial cell lines. 
 
 
 
 
 
 
 
 
 
Antonietta Coppola 
 18
FIGURES, TABLES AND SUPPLEMENTARY DATA 
 
 
 
 
 
figure 1a. homozygosity 
mapping technique: 
purified genomic DNA is 
digested using restriction 
enzymes and legated to an 
adaptor support. An allele 
specific extension is 
performed by using three 
different oligos (two 
recognize the alleles while 
the third recognizes the 
position on the array). 
Fragments are then 
amplified through a PCR 
reaction and labeled with 
two fluorochromes (red 
and green). After the array 
hybridization and washing 
the fluorescent intensity is 
detected by a scanner.  A 
red color indicates 
homozygosity for one 
allele, green color 
indicates homozygosity 
for the other allele; yellow 
indicates heterozygosity. 
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Figure 1b: homozygositymapper output.  Once genotype files are uploaded 
into the homozygositymapper online application a genome wide plot is 
generated with bar charts where red bars indicate the most promising genomic 
regions 
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figure 2: pedigree of family 1 
 
 
 
Patient ID/ Sex/birth 
date 
Age of 
onset  
Neurological features 
Non-neurological 
features 
Neuroimaging 
Last follow-up 
(year) 
IV :2/F/1947 13 
Absences+GTCS+ 
myoclonic  
tremor Normal 2011 
IV:4/F/1948 14 
Absences+GTCS+ 
myoclonic 
- Normal 2011 
IV:6F/1944 25 GTCS - Normal 2011 
IV:7/M/1942 20 GTCS - Normal 2011 
 
table 2: clinical data of family 1; GTCS: generalized tonic-clonic seizures 
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figure 3a: result for family 1. The red square box highlights the homozygous area 
within the linkage area 
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Figure 3b: detail of the homozygous area within the linkage area on chromosome 1 
from figure 3a containing the gene encoding for the Regulator of G-protein 
Signaling 21 (RGS 21). 
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     figure 4: pedigree of family 2 
 
 
 
Patient ID/ 
Sex/birth date 
Age of 
onset  
Neurological features 
Non-
neurological 
features 
Neuroimaging 
Last follow-
up (year) 
IV:1/F/1966 12 Progressive myoclonus, ataxia, mental retardation - 
Slight cerebellar 
atrophy 
2011 
IV:3/F/1973 8 Progressive myoclonus, ataxia, mental retardation - Slight cerebellar 
atrophy 2011 
IV:5/F/1973 10 Progressive myoclonus, ataxia, mental retardation - Slight cerebellar 
atrophy 2011 
IV:5/F/1975 10 Progressive myoclonus, ataxia, mental retardation - Slight cerebellar 
atrophy 2011 
   
table 2:  clinical data of family 2 
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figure  5:  linkage area on chromosome 2 ( within the red box) for family 2. 
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Figure 5a: combined analysis  (linkage+homozygosity mapping) for family 2 showing 
a little homozygosity area on chromosome 2 (squared box) 
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 Figure 5b: detail of the area in figure 5a showing the included genes  
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figure 6: four linkage areas on chromosome 17 for family 2 (within the red box) 
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Figure 6a: combined analysis  (linkage+homozygosity mapping) for family 2 showing 
a little homozygosity area on chromosome 17 (squared box) 
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Figure 6b: detail of the area in figure 6a. 
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Figure 6c: combined analysis  (linkage+homozygosity mapping) for family 2 showing 
a little homozygosity area on chromosome 17 (squared box) 
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Figure 6d: detail of the area in figure 6c showing the included genes 
 
 
 
 
 
 
 
Antonietta Coppola 
 32
 
 
 
 
 
Figure 6e: combined analysis  (linkage+hom mapping) for family 2 showing a little 
homozygosity area on chromosome 17 (squared box) 
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Figure 6f: detail of the area in figure 6e showing the included genes 
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Figure 6g: combined analysis  (linkage+homozygosity mapping) for family 2 showing 
a little homozygosity area on chromosome 17 (squared box) 
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Figure 6h: detail of the area in figure 6g showing the included genes  
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figure 7: pedigree of family 3 
 
Patient 
ID/Sex/birth 
date 
 
Age of 
onset 
Neurological 
features 
Non-neurological 
features Neuroimaging 
Last 
follow-
up 
(year) 
IV:1/M/1968 5(seizures) 
Epilepsy, 
psychomotor 
delay, learning 
difficulties, 
visual failure 
Short stature, 
macroglossia, obesity, 
precocious puberty, 
heart  hypertrophy, 
hypothyroidism, partial 
teeth agenesis, skeletal 
abnormalities 
NA 2011 
IV:3/F/1978 7(seizure) 
Epilepsy, 
psychomotor 
delay, learning 
difficulties, 
visual failure 
Short stature, 
macroglossia, obesity, 
precocious puberty, 
heart hypertrophy, 
hypothyroidism, partial 
teeth agenesis, skeletal 
abnormalities 
NA 2011 
table 3: clinical data of family 3 
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figure 8: phenotype of patients IV:1 e IV:3 from family 3 showing facial 
dysmorphysms (downslanting palpebral fissures, bulbous nose, macroglossia, full 
lower lip) brachydactyly and short stature. 
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Figure 9: pedigree of family 4 showing a consanguineous marriage in the fourth 
previous generation (asterisk). 
 
Patient ID/ 
Sex/birth date 
Age of 
onset  
Neurological features 
Non-
neurological 
features 
Neuroimaging 
Last follow-
up (year) 
V: 1/M/1991 - GTCS; mental retardation 
Asymmetric 
hypotrophy 
(calves); heart 
and kidney 
defects; 
dysmorphisms 
White matter 
changes; CC 
hypoplasia 
2011 
V: 3/M/1994 6m GTCS; mental retardation  
Asymmetric 
hypotrophy 
(calves); heart 
and kidney 
defects; 
dysmorphisms 
White matter 
changes; CC 
hypoplasia 
2011 
table 4: clinical data of family 4. GTCS: generalized tonic clonic seizures; CC: 
corpus callosum 
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figure 10: phenotype of patients IV:1 and IV:3 from family 4 showing facial 
dysmorphysms (hypertelorism, flat nasal bridge, full lower lip, abnormal pinna 
folding) and asymmetric hypotrophic calves.  
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Figure 11: homozygosity mapping result for family 4 showing two RHOs on 
chromosome 1  (from position 176414781 bp to position 243261751 bp) and 19 
(from position20799670 bp to position 39641146 bp). 
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SUPPLEMENTARY DATA 
File 1: list of the genes included in the homozygous area on chromosomes 2 and 17 
for family 2 
 
C Gene 
Start (bp) 
Gene 
End (bp) 
HGNC 
symbol Ensembl Gene ID Description 
17 28364221 29507664 ACCN1 ENSG00000108684 Amiloride-sensitive cation channel 1, neuronal 
17 30925928 30929695 PEX12 ENSG00000108733 Peroxisome assembly protein 12  
17 30938395 31077547 AP2B1 ENSG00000006125 AP-2 complex subunit beta-1  
17 31082792 31094652 RASL10B ENSG00000141150 Ras-like protein family member 10B Precursor  
17 31095650 31104010 GAS2L2 ENSG00000132139 GAS2-like protein 2 (Growth arrest-specific protein 2-like 2) 
17 31112029 31116211 C17orf50 ENSG00000154768 Uncharacterized protein C17orf50 
17 31116989 31146753 MMP28 ENSG00000129270 Matrix metalloproteinase-28 Precursor 
17 31160596 31198350 TAF15 ENSG00000172660 TATA-binding protein-associated factor 2N 
17 31206073 31220008 C17orf66 ENSG00000172653 Uncharacterized protein C17orf66  
17 31222608 31231910 CCL5 ENSG00000161570 C-C motif chemokine 5 Precursor  
17 31269197 31281893 RDM1 ENSG00000187456 RAD52 motif-containing protein 1  
17 31285638 31294787 LYZL6 ENSG00000161572 Lysozyme-like protein 6 Precursor 
17 36332478 36347362 KRT23 ENSG00000108244 Keratin, type I cytoskeletal 23  
17 36368195 36376670 KRT39 ENSG00000196859 Keratin, type I cytoskeletal 39  
17 36387494 36396152 KRT40 ENSG00000204889 Keratin, type I cytoskeletal 40  
17 37808001 37828800 PTRF ENSG00000177469 Polymerase I and transcript release factor   
17 37864388 37928122 ATP6V0A1 ENSG00000033627 V-type proton ATPase 116 kDa subunit a isoform 1 
17 37941477 37949990 NAGLU ENSG00000108784 Alpha-N-acetylglucosaminidase Precursor  
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17 37954758 37960750 HSD17B1 ENSG00000108786 Estradiol 17-beta-dehydrogenase 1  
17 37967618 37971821 COASY ENSG00000068120 Bifunctional coenzyme A synthase  
17 37972604 37978746 MLX ENSG00000108788 Max-like protein X  
17 37977881 37983375 PSMC3IP ENSG00000131470 Homologous-pairing protein 2 homolog  
17 37985066 38014928 FAM134C ENSG00000141699 Protein FAM134C  
17 38015220 38020773 TUBG1 ENSG00000131462 Tubulin gamma-1 chain  
17 38064837 38072547 TUBG2 ENSG00000037042 Tubulin gamma-2 chain  
17 38073463 38082495 PLEKHH3 ENSG00000068137 
Pleckstrin homology domain-containing family H member 3 
Precursor 
17 38084946 38087371 CCR10 ENSG00000184451   
17 38088158 38105358 CNTNAP1 ENSG00000108797 Contactin-associated protein 1 Precursor  
17 38105820 38150574 EZH1 ENSG00000108799 Enhancer of zeste homolog 1 (ENX-2)  
17 38166731 38168585 RAMP2 ENSG00000131477 Receptor activity-modifying protein 2 Precursor  
17 38178980 38185142 VPS25 ENSG00000131475 Vacuolar protein-sorting-associated protein 25 
17 38186222 38202587 WNK4 ENSG00000126562 Serine/threonine-protein kinase WNK4  
17 38203179 38204248 CCDC56 ENSG00000183978 Coiled-coil domain-containing protein 56  
17 38204464 38216179 CNTD1 ENSG00000176563 Cyclin N-terminal domain-containing protein 1   
17 38215678 38229807 BECN1 ENSG00000126581 Beclin-1 
17 38238949 38249301 PSME3 ENSG00000131467 Proteasome activator complex subunit 3 
17 38250135 38256248 AOC2 ENSG00000131480 Retina-specific copper amine oxidase Precursor  
17 38256727 38263664 AOC3 ENSG00000131471 Membrane primary amine oxidase  
17 38306341 38318912 G6PC ENSG00000131482 Glucose-6-phosphatase 
17 38356073 38386033 AARSD1 ENSG00000108825 Alanyl-tRNA synthetase domain-containing protein 1  
17 38386108 38399233 RUNDC1 ENSG00000198863 RUN domain-containing protein 1   
17 38403972 38408482 RPL27 ENSG00000131469 60S ribosomal protein L27  
17 38412351 38419998 IFI35 ENSG00000068079 Interferon-induced 35 kDa protein 
17 38420148 38427985 VAT1 ENSG00000108828 Synaptic vesicle membrane protein VAT-1 homolog 
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17 38430784 38437583 RND2 ENSG00000108830 Rho-related GTP-binding protein RhoN Precursor 
17 38449840 38530994 BRCA1 ENSG00000012048 Breast cancer type 1 susceptibility protein 
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